DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Patients with previously untreated mantle cell lymphoma (MCL) have relied on autologous stem cell transplant (ASCT) for more than 20 years; the current standard of care entails high-dose cytarabine-containing chemoimmunotherapy, ASCT, and rituximab maintenance. A recent clinical trial’s findings, which revealed that FFS was superior to ASCT when ibrutinib medication was added, may change this.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
